Swedish private equity company EQT AB (STO: EQT) said on Tuesday it has agreed to acquire the specialist biologics business Corza Biosurgery from global medical technology company Corza Medical, via its EQT X fund.

Corza Biosurgery develops complex surgical biologics, primarily TachoSil, an active dual-action patch used to control bleeding and seal tissue during surgery. Manufactured at its facility in Linz, Austria, the patch is used in more than 50 countries across cardiovascular, neuro, hepatic and thoracic procedures, supported by over 540 clinical trial publications.

TachoSil is designed to help surgeons achieve rapid haemostasis and effective tissue sealing, supporting shorter procedures, fewer complications and faster recovery. EQT believes demand will continue to rise as surgical volumes increase due to ageing populations, chronic disease and advances in surgical techniques.

EQT plans to invest in commercial expansion, innovation and global scaling, with a particular focus on accelerating growth in the US and increasing adoption in underpenetrated markets. It also sees scope to build a broader biosurgery platform through partnerships and acquisitions.

The transaction is subject to customary conditions and approvals and is expected to close in Q4 2026. EQT X is expected to be 80–85% invested following completion.